# US 2024/0197791 A1 · Composition containing mesenchymal stem cell and vascular endothelial progenitor cell as active ingredient for prevention or treatment of occlusive vascular disease or complication thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197791 A1
- Document ID: US20240197791A1
- Status: Published application
- Kind: A1
- Application number: 18/286,954
- Filed: 2022-04-08
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Assignees: University-Industry Cooperation Group of Kyung Hee University; Elphis Cell Therapeutics
- Applicants: University-Industry Cooperation Group of Kyung Hee University; Elphis Cell Therapeutics
- Inventors: Hyun Sook HONG; Dae Yeon HWANG; Suna KIM; Youngsook SON
- Web page: https://patentgrep.com/patent/US20240197791A1

## CPC

- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/38: Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a composition comprising vascular endothelial progenitor cells and mesenchymal stem cells as active ingredients for prevention or treatment of occlusive vascular diseases or complications thereof. Since it was found that vascular endothelial progenitor cells and mesenchymal stem cells remarkably improved vascularization ability upon application thereof in combination, the present invention has the effect of providing a new cell therapy product for prevention or treatment of occlusive vascular diseases or ulcers resulting therefrom, and a preparation method therefore.

## Claims

### Claim 1

A method for treating an occlusive vascular disease or an ulcer resulting therefrom, the method comprising administering a composition comprising vascular endothelial progenitor cells and mesenchymal stem cells as active ingredients to a subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the vascular endothelial progenitor cells and the mesenchymal stem cells are human bone marrow-mesenchymal stem cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the occlusive vascular disease is a disease selected from the group consisting of cerebrovascular disease (CVD), cardiovascular disease, arteriovascular disease, coronary artery disease (CAD) and peripheral artery disease (PAD).

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is administered at a dose of 1.2×105 to 1.2×107 cell/kg body weight.

### Claim 5 (depends on 1)

The method of claim 1, wherein the vascular endothelial progenitor cells are located in vascular cells when administered to the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells are located in pericytes when administered to the subject.

### Claim 7

A preparation method of a composition for prevention or treatment of an occlusive vascular disease or an ulcer resulting therefrom, comprising mixing vascular endothelial progenitor cells and mesenchymal stem cells.

### Claim 8 (depends on 7)

The preparation method of the composition of claim 7, wherein the vascular endothelial progenitor cells and the mesenchymal stem cells are mixed at a ratio of 2:1.

### Claim 9 (depends on 7)

The preparation method of composition of claim 7, wherein the vascular endothelial progenitor cells and the mesenchymal stem cells are human bone marrow-mesenchymal stem cells.

### Claim 10

(canceled)

### Claim 11

(canceled)